Diabetes
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Communication Preferences
Sign Out
Sign In | Create Account
  • Diabetes Home
    • Products
      Diabetes Treatments
    • Professional Resources
      Product Resources Library Insulin & Type 1 Diabetes
    • Professional Training
      Insulin Pen Training
  • Sample Requests
    • Diabetes Education
      Clinical Education Library Diabetes Risk Assessment Tool Diabetes & Cardiovascular Disease
    • Treatment Guidelines
      ADA Standards of Care AACE Diabetes Guidelines
    • Additional Resources
      Utilizing Your EHR Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Library
    • Prescription Savings & Coverage
      Savings Cards Insurance Coverage Affordability Resources
    • Support Program
      Diabetes Management Cardiovascular Risk Management
  • Sign In
    Create Account
    • Account Settings
    • Communication Preferences
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Diabetes & Cardiovascular Disease
Diabetes & Cardiovascular Disease
  • Overview
  • Clinical Guidelines
  • Multidisciplinary Care
  • Talking to Patients

Guidelines for treating cardiovascular risk in patients with type 2 diabetes

Actor portrayal

Major medical societies support use of GLP-1 RAs with proven CVD benefit1-5,a

American College of Cardiology logo

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

See pathway
American Heart Association® and American Stroke Association® logos

2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

See guideline
American Diabetes Association® logo

2022 Standards of Medical Care in Diabetes

View recommendations
American Association of Clinical Endocrinology logo

Consensus Statement by the AACE/ACE on the Comprehensive Type 2 Diabetes Management Algorithm

View statement

aAccording to the ADA, “proven CVD benefit” means it has a label indication of reducing CVD events.1  

GLP-1 RA=glucagon-like peptide-1 receptor agonist; CVD=cardiovascular disease; ADA=American Diabetes Association.

GLP-1 RA icon

In patients with established ASCVD,b the use of a GLP-1 RA or SGLT-2i with demonstrated CVD benefita should be considered independently of baseline A1C or individual A1C target.1-5,c  


A GLP-1 RA or SGLT-2i is recommended for initial therapy in patients with T2D with or at high risk for ASCVD regardless of treatment with metformin.1

bThe ACC defines ASCVD as: a history of an acute coronary syndrome or myocardial infarction (MI), stable or unstable angina, coronary heart disease with or without revascularization, other arterial revascularization, stroke, or peripheral artery disease assumed to be atherosclerotic in origin.2  

cPlease refer to the 2022 ADA Standards of Medical Care in Diabetes, the 2020 AACE/ACE Consensus Statement, the 2020 AHA Scientific Statement on Cardiorenal Protection With the Newer Antidiabetic Agents, the 2020 ACC Expert Consensus Decision Pathway, or the 2021 AHA/ASA Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack.

 

ASCVD=atherosclerotic cardiovascular disease; SGLT-2i=sodium-glucose co-transporter-2 inhibitor; ACC=American College of Cardiology; AHA=American Heart Association; ASA=American Stroke Association.

Quick-reference summaries to download or share

2020 Expert Consensus Decision Pathway Booklet
PDF
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
2020 Expert Consensus Decision Pathway Booklet
Brochure summarizing the American College of Cardiology's Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes.
Download
Summary of ADA Treatment Recommendations for Type 2 Diabetes
PDF
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Summary of ADA Treatment Recommendations for Type 2 Diabetes
A summary algorithm that includes an ADA-recommended overall approach for glucose-lowering medication in type 2 diabetes.
Download

Talking to diabetes patients about CV risk

Do your patients know the facts about T2D and ASCVD? This page provides patient-friendly stats and descriptions to help them understand their risks and options.

See information

Actor portrayal

References:

  1. American Diabetes Association. Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S1-S264.
  2. Das SR, Everett BM, Birtcher KK, et al. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(9):1117-1145.
  3. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2020 Executive Summary. Endocr Pract. 2020;26(1):107-139.
  4. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364-e467.
  5. Rangaswami J, Bhalla V, de Boer IH, et al. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association. Circulation. 2020;142(17):e265-e286.
Diabetes
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Diabetes Home
  • Product Information
    Products
    • Diabetes Treatments
    Professional Resources
    • Product Resources Library
      Insulin & Type 1 Diabetes
    Professional Training
    • Insulin Pen Training
  • Sample Requests
  • Professional Education
    Diabetes Education
    • Clinical Education Library
      Diabetes Risk Assessment Tool
      Diabetes & Cardiovascular Disease
    Treatment Guidelines
    • ADA Standards of Care
      AACE Diabetes Guidelines
    Additional Resources
    • Utilizing Your EHR
      Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Library
    Prescription Savings & Coverage
    • Savings Cards
      Insurance Coverage
      Affordability Resources
    Support Program
    • Diabetes Management
      Cardiovascular Risk Management

novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
Non-US Health Care Professionals, please go to pro.novonordisk.com.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2022 Novo Nordisk All rights reserved. US22HCP00011 August 2022

Quick links

Request medication samples

Diabetes treatment guidelines

Patient savings card offer

Patient support program